Nektar Therapeutics Common Stock (NASDAQ: NKTR)
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (ii) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial’s results; (iii) accordingly, the REZOLVE-AA trial’s overall integrity and prospects were overstated; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.